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INTRODuCTION
Multiple sclerosis (MS) – a chronic neurodegenerative 
disease of autoimmune nature – is an outstanding med-
ical–social problem, because it affects mainly the young 
and middle-aged. the problem of MS treatment still has 
no satisfactory solution, and to this day there are several 
medicines (therapies) able to suppress MS to some extent, 
but not to fully cure it. neuronal degradation occurs in the 
brain of MS patients due to the destruction of the neuron’s 
myelin sheath. One biochemical characteristic which dif-
ferentiates myelin from other biological membranes is the 
high lipid/protein ratio. Proteins comprise 25–30% of the 
mass of the myelin sheath dry matter. About 30% of all 
myelin proteins are three isoforms of the myelin basic pro-
tein (MBP). MBP is one of the main autoantigen in MS. ear-
lier, we and other authors showed that catalytic antibodies 
[2–5] and some proteases [6–9] may be involved in MBP 
degradation. It is known that every eukaryotic cell contains 
a special compartment for targeted protein degradation 
(proteasome), which is a high molecular protease complex. 
One of the proteasome's functions is to produce peptides, 
which will then be presented on the cell membrane using 
main histocompatibility complex (MHc) molecules of the 
first or second class [10]. there are definite reasons to as-
sume that proteasome directly takes part in specific MBP 
degradation. the details of this process are still unclear. 
In this work, the specific features of MBP degradation by 
proteasome were studied. 
It is well-known that the 20S proteasome (a multicata-
lytic proteinase complex) is an oligomeric high-molecular-
weight (700 kDa) proteinase that can be isolated separately. 
this complex is the catalytic core of the larger 26S proteas-
ome, which also contains one or two regulatory 19S subunits. 
It was shown that both 20S and 26S proteasomes are able 
to degrade proteins, including the MBP [11, 12]. the ques-
tion of the site-specificity of MBP degradation by the pro-
teasome remained open. It is also known that, during many 
inflammatory pathological processes, the standard protease 
complex (constitutive proteasome) transforms into a form 
of immunoproteasome, which has an alternative specificity 
and catalytic efficiency with respect to intracellular proteins 
processing. It is very likely that this ‘switching’ is closely re-
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lated to different antigen presentation in healthy and in the 
pathological states. the pattern of MBP degradation by pro-
teasome has not been studied before. 
RESuLTS AND DISCuSSION
Proteasome was isolated and purified using the technique 
described in [13] with slight modifications. At the first stage, 
the degradation of MBP (from bovine brains, isoform with 
MW 18,5 kDa) was performed by a full 26S complex and cat-
alytic 20S subparticle isolated from mice liver. It is shown 
in Fig. 1 that the incubation of MBP with 20S and 26S pro-
teasomes leads to progressive MBP degradation. the 20S 
proteasome completely hydrolyzed MBP in 45 min, while 
the 26S proteasome requires 85 min to degrade the same 
amount of MBP. the variation in reaction rates could be as-
cribed to different proteasome concentrations: in the case 
of 20S proteasome, the enzyme/substrate ratio was 2.7 : 1 
(g/g of protein) or 1 : 14.5 (mol/mol); in the case of the 26S 
proteasome, the enzyme/substrate ratio was lower, namely 
1 : 1 (g/g of protein) or 1 : 110 (mol/mol). the proteasome 
amount was estimated by the Lowry method, using bovine 
serum albumin as a standard. 
the MBP hydrolyzates, processed using 20S and 26S 
protease complexes from the liver of outbreed mice, were 
fractionated by reverse-phase HPLc on c4 column (Waters, 
Delta- Pak, 300 Å). Although the general patterns of elution 
profiles of hydrolyzates were similar, several differences in 
elution profiles were observed. In particular, it should be 
noted that some peaks that concurred for 20S and 26S pro-
teasomes differed in their amount of matter; moreover, in 
the 26S hydrolyzate, new fractions appeared. thus, the 26S 
degradation pattern of MBP somewhat altered compared to 
the 20S pattern. these differences can be explained by the 
unequal accessibility to proteolysis of MBP sites located on 
the surface and in the depth of the protein globule, as well as 
by their pronounced secondary structure. In the case of the 
26S proteasome, the accessibility of different sites of MBP 
was not of great importance, because the 19S subparticle 
contains subunits responsible for the denaturation of protein 
molecules that are to be degraded. 
the pool of proteasomes is heterogenous and consists of 
macromolecular complexes of several types, with catalytic 
subunits referred to the so-called constitutive type (β1, β2, 
and β5) or immune type (β1i, β2i, and β5i) (Fig. 2). Six cat-
alytic subunits of proteasome expressed three types of ac-
tivities, namely chymotrypsin-like (cleavage of the peptide 
bond on the carboxyl site of hydrophobic and aromatic ami-
no acids Leu, tyr, Phe), trypsin-like (hydrolysis after posi-
tively charged Lys and Arg), and caspase-like (hydrolysis 
after negatively charged Asp and Glu) [14]. 
the constitutive-to-immunoproteasome ratios have 
clearly defined tissue-specificity and, to a considerable de-
gree, depend on the immune state of the organism. For ex-
ample, more than 90% of the total amount of proteasomes in 
the brain are constitutive, but in the spleen about 90–95% of 
proteasome are immunoproteasomes. Besides, in any tissue 
under interferon gamma exposure, the immune catalytic 
subunits are produced extensively, being integrated into the 
newly assembled multicatalytic complexes [15]. 
It was shown earlier that replacing constitutive catalytic 
subunits with immune leads to a change in hydrolysis spe-
cificity and to an increase in its velocity. Immunoproteas-
ome complexes almost lose their ability to hydrolyze peptide 
bonds after aspartic and glutamic acids residues (caspase-
like activity);however, a lot more often the hydrolysis takes 
place after hydrophobic and, especially, branched hydro-
phobic amino acid residues. therefore, during immunopro-
teasome processing, an increased amount of peptides bearing 
hydrophobic amino acids on the c-end is produced. Because 
hydrophobic amino acids on the c-end of peptides are im-
portant anchor fragments for binding with MHc I class mol-
Fig. 1. The time dependence of the level of MBP hydrolysis by protea‑
some. Labels: ○ 20S proteasome,   26S proteasome, isolated from
outbreed mice liver. 
Fig. 2.The proteasome–immunoproteasome equilibrium. Immune cata‑
lytic subunits produced in cells exposed to interferon gamma. 86 | ActA nAturAe |  № 1 2009
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ecules, the change in hydrolysis specificity leads to an in-
crease in the production of peptides able to form complexes 
with MHc molecules. then, the fragments bounded to MHc 
are presented on the outer cellular membrane to immune 
cells. thus, cells bearing immunoproteasome should more 
effectively present their own antigens. 
It is also known that 〈-subunits of the proteasome cata-
lytic 20S subparticle function as a gate forming an axial 
channel that regulates the influx and efflux of proteins and 
their degradation products by the opening and closing of 
the entrance to the so-called catalytic chamber. therefore, 
the closing of this channel may enable complete substrates 
degradation by preventing the efflux of partially hydro-
lyzed peptides [16]. It was also shown [17] that the opening 
of the channel strongly affects the proteolysis kinetics and 
the distribution of hydrolytic fragments obtained in vitro 
with respect to the peptide length. If the channel is open, the 
hydrolysis rate increases; however, in this case, the mean 
length of produced fragments also increases by 40%. thus, 
the higher hydrolysis rate of immunoproteasome should re-
sult in longer degradation products (peptides), which will 
better bind to MHc molecules and, thus, will more effective-
ly be presented on the cell's surface. 
It is well established that SJL/J mice are genetically 
predisposed to the development of experimental autoim-
mune encephalomyelitis. this pathology is the clinically 
relevant animal model of multiple sclerosis (MS). using 
immunoblotting we studied the composition of the protea-
some pool in the brains of SJL/J mice, and it was revealed 
that the immunoproteasome amount is increased in com-
parison to Balb/c mice brains (data not shown). there-
fore, at the next stage of the study, the proteasomes from 
the brains of SJL/J and Balb/c mice were isolated, and 
the proteolysis of MBP by those proteasome samples was 
studied. 
the MBP hydrolyzates obtained using proteasomes iso-
lated from mice of the two strains were studied by Lc-MS. 
Figure 3 shows the complete amino acid sequence of MBP, 
and the arrows indicate the major fragments produced by 
proteasome pools from the above-mentioned sources. the 
thickness of the arrows indicates the relative amount of cor-
responding peptide in hydrolyzate. 
In the MBP sequence, several regions could be attributed 
to immunodominant protein regions: 12-31, 82-98, 110-128 
and 144-169; fragment 85-98 is the so-called encephalito-
genic epitope, which can activate the immune response. 
Fig. 4. The length 
distribution of pep‑
tides found in MBP 
hydrolyzates ob‑
tained using protea‑
some pools from the 
brains of (a) Balb/C 
mice and (b) SJL/J/J 
mice. Bars on the 
diagram correspond 
to the experimental 
value of the ionic cur‑
rent for the peptides 
of relevant lengths 
as determined by 
LC‑MS. 
Fig. 3. Amino acid sequence of MBP.
Arrows mark the proteolytic peptides 
determined by chromato‑mass spec‑
trometry in hydrolyzates of MBP by 
proteasome from the brains of SJL/J/J 
mice (upper picture) and of Balb/C 
mice (lower picture). The arrow’s 
thickness indicates the frequency 
of occurrence of the corresponding 
peptide. Color rectangles show the 
immunodominant regions of MBP.reSeArcH ArtIcLeS
 № 1 2009  | ActA nAturAe | 87
It should be noted that MBP degradation by proteasome 
from outbreed mice liver, both by the full 26S complex and 
the catalytic core, does not lead to the generation of immu-
nogenic epitopes, all of which were exposed to subsequent 
fragmentation inside the proteasome catalytic chamber. 
In MBP hydrolyzate by proteasome isolated from the 
brains of SJL/J and Balb/c mice, almost the only hydrolytic 
site where proteasome exhibits its caspase-like activity was 
the bond between amino acid residues Asp81-Glu82, close to 
the beginning of the encephalitogenic peptide. 
the MBP hydrolysis pattern by proteasome isolated from 
the brains of SJL/J and Balb/c mice differed to some ex-
tent. In the brains of the autoimmune mice, the generated 
epitopes could be considerably better colocalized with im-
munodominant regions of the protein. under the action of 
the SJL/J mice proteasome pool on the myelin basic protein, 
up to a quarter of all obtained hydrolytic fragments were 
made up of encephalitogenic peptides. the Balb/c mice 
strain proteasome produces half the amount of that peptide. 
Moreover, fragments obtained using a Balb/c mice-brain 
proteasome poorly correlate to the recognition regions of 
MHc class II molecules. 
Figure 4 shows the length distribution of peptides in cor-
responding hydrolyzates. On the vertical axis, the experi-
mental values of the ionic current obtained using Lc-MS for 
a peptide of a given length is shown. It can be seen that the 
maximum of the distribution is on peptides having 8 ami-
no acids in length, both in case of proteasome isolated from 
the brains of SJL/J or Balb/c mice. However the relative 
values of the average ionic current for these two samples 
differed drastically, which can be an argument for substan-
tially more fragments of the given length in the case of au-
toimmune mice. In the hydrolyzates studied, peptides with 
an even number of amino acid residues predominate, and no 
peptides shorter than 4 residues were detected. these data 
are in good agreement with the literature [18] and with the 
opinion that one of the main roles for proteasome in cells is 
the generation of peptides for subsequent presentation on 
MHc class I molecules, which can bind peptides of 8–10 
amino acids in length. Longer peptides found in hydrolyzates 
could be further processed to shorter fragments inside the 
cell and presented on the MHc I class molecules, and they 
could also participate in presentation on MHc II class mol-
ecules [10]. 
CONCLuSIONS 
In conclusion, in our work it was shown that both 20S and 
26S proteasomes are able to hydrolyze the myelin basic pro-
tein, and the proteasome/MBP molar ratio was found to be 1 
: 14.5 and 1 : 110, respectively; the complete hydrolysis time 
was 45 and 85 min, respectively. After separating hydro-
lyzates by HPLc, the molecular weights of the fragments 
were determined by MALDI mass spectrometry. After ana-
lyzing the amino acid sequence of MBP, the proteolytic sites 
were identified. 
It was demonstrated that the nonubiquitinated myelin 
basic protein is a good substrate for both 20S and 26S pro-
teasomes. this was the first work to identify the sites of 
MBP proteolysis using a proteasome isolated from the brains 
of SJL/J and Balb/c mice and to show significant differ-
ences in the degradation pattern of this autoantigen. these 
findings could argue for a better presentation of MBP frag-
ments on the MHc molecules in the case of mice genetically 
predisposed to the development of experimental autoim-
mune encephalomyelitis.  
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